Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1931-1940 of 2922 for cancer

Edit search filters
  1. A Study To Evaluate The Safety And Effectiveness Of CAEL-101 And Plasma Cell Dyscrasia Treatment Vs. Placebo And Plasma Cell Dyscrasia Tretment To Treat Patients With Mayo Stage IIIb AL Amyloidosis

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label

    Rochester, MN

  3. A Study To Evaluate The Safety And Effectiveness Of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant As Treatment For Locally Advanced (Inoperable) Or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer

    Jacksonville, FL, Rochester, MN

  4. A Study Of Pembrolizumab (MK-3475) Versus Placebo In Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy In The Treatment Of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

    Rochester, MN

  5. TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC)

    Rochester, MN

  6. A Study to Compare Venetoclax with Fulvestrant vs. Fulvestrant Alone in Women with Locally Advanced or Metastatic HER2-negative Cancer who Have Progressed or Recurred on a CDK4/6 Inhibitor

    Scottsdale/Phoenix, AZ

  7. Adding The Immunotherapy Drug Cemiplimab To Usual Treatment For People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy And Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    Rochester, MN

  8. Safety And Tolerability Of Atezolizumab (ATZ) In Combination With Radium-223 Dichloride (R-223-D) In Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With An Androgen Pathway Inhibitor

    Jacksonville, FL, Rochester, MN

  9. A Phase 3 Randomized, Placebo-controlled, Double-blind Study Of Niraparib In Combination With Abiraterone Acetate And Prednisone Versus Abiraterone Acetate And Prednisone For Treatment Of Subjects With Metastatic Prostate Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  10. A Study to Assess the Effectiveness, Safety, and Drug/Body Interactions of Rovalpituzumab for Third-Line and Later Treatment of Patients with Small Cell Lung Cancer that has Returned or is Resistant to Treatment

    Rochester, MN

.

Mayo Clinic Footer